Fig. 1 From: Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE studyCumulative ≥CR rates by time. ≥CR, complete response or better; <CR, less than complete response; KRd, carfilzomib, lenalidomide, and dexamethasone; Rd, lenalidomide and dexamethasone. aData are from safety population: cumulative ≥CR rates achieved according to time from treatment startBack to article page